INT131 (Figure 2), for example, a novel, nonthiazolidinedione (TZD), selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator [9], is in development by InteKrin Therapeutics Inc. for the treatment of type 2 diabetes mellitus. This evidence concerns the gene PPARG and type 2 diabetes mellitus.